Calyxo announced that it closed a Series F financing round worth $40 million.
Ally Bridge Group and Janus Henderson Investors led the financing. Questa Capital, Avidity Partners and CRG participated, too. This funding adds to $50 million raised in 2023.
Related: E2 raises $80M Series C for Hēlo thrombectomy system
The financing comes on the heels of the 40,000th patient treated with the company’s CVAC all-in-one aspiration-based kidney stone removal system. The company plans to use funds to expand the commercial infrastructure around CVAC.
Pleasanton, California-based Calyxo also plans to use funds to advance clinical and health economic evidence generation through ongoing and future clinical studies. It also intends to support continued innovation in kidney stone care.
CVAC uses irrigation and aspiration to remove kidney stones. The design aims to minimize residual stone burden. Calyxo describes it as the only stone clearance solution integrating ureteroscopy, laser lithotripsy, irrigation and aspiration in one device. The company said incorporating direct visualization with dedicated irrigation channels and a large aspiration lumen enables effective and efficient kidney stone aspiration.
“This financing marks an important inflection point for Calyxo,” said Joe Catanese, CEO of Calyxo. “More than 40,000 patients have now been treated with the CVAC System. Real-world experience, together with an established body of clinical evidence, indicates that the CVAC System is moving beyond early adoption and becoming an important part of the standard of care in kidney stone treatment. This financing allows us to move faster in advancing our technology and expanding the evidence base to further improve patient care.”
